FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO-50 | Enhanced integration and synergy in EEG- and fNIRS-based networks in migraine patients following three-month galcanezumab treatment: associations with long-term clinical effects Giulia Paparella,1,2 Marianna La Rocca,3 Livio Clemente,1 Emmanuella Ladisa,1 Chiara Abbatantuono,1 Elena Ammendola,1 Marianna Diletta Delussi,4 Katia Ricci,1 Giusy Tancredi,1 Antonio Lacalamita,3 Alfonso Monaco,3 Nicola Amoroso,5 Sebastiano Stramaglia,3 Roberto Bellotti,3 Marina de Tommaso1 | 1Neurophysiopathology Unit, Department of Translational Biomedicine and Neuroscience (DiBraiN), University of Bari Aldo Moro, Bari, Italy; 2IRCCS Neuromed, Pozzilli (IS), Italy; 3Interateneo Department of Physics "M. Merlin", University of Bari Aldo Moro, Bari, Italy; 4Department of Education, Psychology, Communication (For.Psi.Com.), University of Bari Aldo Moro, Bari, Italy; 5Department of Pharmacy–Drug Sciences, University of Bari Aldo Moro, Bari, Italy
136 -
PO-78 | No changes in blood pressure assessed with the 24-hour Holter monitoring in patients treated with anti-CGRP monoclonal antibodies: a prospective observational study (SAFHYPER) Flavia Lo Castro,1 Niccolò Bonini,2 Luigi Francesco Iannone,1,3 Alberto Boccalini,1 Daria Brovia,1 Luca Pani,1,3 Giuseppe Boriani,2,3 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Cardiology Division, AOU Policlinico di Modena, Modena, Italy; 3Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy
304 -
PO-16 | Neurophysiological effects of atogepant in high-frequency episodic migraine B. Agostini,1,2 F. Cammarota,1,2 R. De Icco,1,2 V. Grillo,1,2 G. Vaghi,1,2 F. Bighiani1,2, M. Corrado,2 A. Antoniazzi,1,2 M. Giraudo,1,2 A. Solfrizzi,1,2 R. Greco,2 C. Demartini,1,2 A. Zanaboni,1,2 M. Francavilla,1,2 S. Facchetti,1,2 G. Sances,2 C. Tassorelli1,2 | 1Department of Brain and Behavioral Sciences, University of Pavia; 2Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy
227 -
PO-02 | Migraine in youth: a double challenge to cognition and emotion Samuela Tarantino,1 Martina Proietti Checchi,1 Laura Papetti,1 Fabiana Ursitti,1 Gabriele Monte,1 Giorgia Sforza,1 Massimiliano Valeriani,1-3 | 1Developmental Neurology Unit, Bambino Gesù Children's Hospital, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Rome, Italy; 2Systems Medicine Department, Tor Vergata University of Rome, Rome, Italy; 3Translational Pain Neuroscience and Precision Medicine, CNAP, Dept. of Health Science and Technology, School of Medicine, Aalborg University, Denmark
263 -
PO-56 | The role of bilateral greater occipital nerve block in resistant chronic migraine with medication overuse Leonardo Troilo, Letizia Curto, Giulia Procopio, Antonia Di Chirico, Gabriele Siciliano, Sara Gori, Filippo Baldacci | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy
180 -
PO-84 | Inhibiting the peripheral degradation of anandamide reduces trigeminal hyperalgesia in a model of dural neurogenic inflammation via a CB1/CB2-independent mechanism Chiara Demartini,1 Rosaria Greco,1 Miriam Francavilla,1,2 Sara Facchetti,1,2 Cristina Tassorelli1,2 | 1Section of Translational Neurovascular Research, IRCCS Mondino Foundation, Pavia, Italy; 2Department of Brain and Behavioral Sciences, University of Pavia, Pavia, Italy
275 -
PO-75 | Network meta-analysis comparing efficacy and safety outcomes of atogepant, rimegepant, and galcanezumab in patients with episodic migraine after including CHALLENGE-MIG Trial Jessica Ailani,1 Pranav Gandhi,2 Anjana Lalla,2 Peter McAllister,3 Tanya Bilchik,4 Stephanie Nahas,5 David Rowe,6 Cristiano Piron,6 Kari Kelton,6 Raffaello Masselli*, Rashmi Halker Singh7 | 1MedStar Health, Washington DC, USA; 2AbbVie, North Chicago, IL, USA; 3New England Institute for Neurology and Headache, Stamford, CT USA; 4Department of Neurology, Yale School of Medicine, New Haven, CT, USA; 5Department of Neurology, Thomas Jefferson University, Philadelphia, PA USA; 6Medical Decision Modeling Inc., Indianapolis, IN, USA; 7Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy. This individual has been added to this publication author by-line, with the permission of the original authors, for the express purpose of conducting the presentation at a local congress or in a local language. He did not contribute to the content of the publication.
390 -
PO-54 | Patient perspectives on physiotherapy interventions for migraine: a pre- and post-intervention qualitative study Zhiqi Liang,1 Caitlin Scott,1 Felix Cabrera Manrique,1 Sumin Kim,1 Chun Shun Lee,1 Bixiang Cheng,1 Chun Yiu Kwok,1 Matteo Castaldo2 | 1University of Queensland; 2Parma University, Italy
256 -
PO-12 | The long-term efficacy on migraine of non-ketogenic low-carb diet after treatment with ketogenic diet Silvia Favaretto,1 Francesco Francini Pesenti2 | 1Headache centre, Neurology Unit, Department of Neuroscience, University Hospital of Padua; 2Department of Medicine (DIMED), Clinical Nutrition, University Hospital of Padua, Italy
524 -
OC-05 | Mid-term effectiveness and tolerability of atogepant in the prevention of migraine: a real life, prospective, multicentric study (the STAR study) Fabrizio Vernieri,1 Luigi Francesco Iannone,2,3 Gabriele Sebastianelli,4 Flavia Lo Castro,2, Federico De Santis,5 Michele Corrado,6 Marilena Marcosano,1 Raffaele Ornello,5 Licia Grazzi,7 Danilo Antonio Montisano,7 Francesco De Cesaris,8 Antonio Munafò,8 Gianluca Avino,9 Michele Trimboli,10 Maria Albanese,11 Antonio Russo,12 Giorgio Dalla Volta,13 Marina Romozzi,14 Paola Merlo,15 Maria Pia Prudenzano,16 Maria Rosaria Valente,17 Innocenzo Rainero,18 Giada Giuliani,19 Luisa Fofi,1 Alberto Doretti,20 Gloria Vaghi,6 Francesca Pistoia,5 Delfina Ferrandi,21 Stefania Battistini,22 Simona Sacco,5 Simona Guerzoni,2 Claudia Altamura1 on behalf of the Italian Headache Registry (RICe) Study Group | 1Fondazione Policlinico Campus Bio-Medico, Roma; 2AOU Policlinico di Modena; 3Università di Modena e Reggio Emilia. 4Sapienza University of Rome Polo Pontino, Latina; 5University of L’Aquila; 6University of Pavia, Pavia, Italy and IRCCS Mondino Foundation, Pavia; 7IRCCS Istituto Neurologico Carlo Besta, Milano; 8AOU Careggi, Firenze; 9SOC Neurologia, Ospedale di Prato, Prato; 10Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 11Università Roma Tor Vergata, Roma; 12Università della Campania "Luigi Vanvitelli", Napoli; 13U.O Neurologia, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia; 14Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Roma; 15UO di Neurologia, Humanitas Gavazzeni, Bergamo; 16Clinica Neurologica "L. Amaducci", Azienda Ospedaliero-Universitaria Consorziale di Bari; 17Dipartimento di Neuroscienze, Azienda Sanitaria Universitaria Integrata di Udine; 18Dipartimento di Neuroscienze, Città della Salute e della Scienza di Torino; 19Centro per la diagnosi e terapia delle cefalee, Policlinico Umberto I, Roma; 20IRCCS Istituto Auxologico Italiano, Milano; 21AOU Alessandria; 22University of Siena, Siena, Italy
283 -
PO-19 | Unraveling the spectrum of migraine resistant to treatments: searching for novel biological PHEnotypes and theRApeutic approaches (SPHERA project) M. Giraudo,1,2 R. De Icco,1,2 G. Vaghi,1,2 V. Grillo,1,2 F. Bighiani,1,2 M. Corrado,2 A. Antoniazzi,1,2 F. Cammarota,1,2 B. Agostini,1,2 A. Solfrizzi,1,2 M. Allena,2 E. Guaschino,2 N. Ghiotto,2 R. Greco,2 C. Demartini,2 A. Zanaboni,1,2 M. Francavilla,1,2 S. Facchetti,1,2 G. Sances,2 C. Tassorelli1,2 | 1Department of Brain and Behavioral Sciences, University of Pavia; 2Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia, Italy
322 -
-
PO-10 | Differential diagnosis between symptomatic focal occipital epilepsy and headache: a case report Federica Molaschi,1 Barbara Lauria,2 Giulia Grasso,2 Cristina Vassia,2 Francesca Torta,3 Antonia Versace,2 Carlotta Canavese3 | 1University of Turin, SC U Child Neuropsychiatry, Regina Margherita Hospital, Turin; 2Department of Pediatric Emergency, Pediatric Headache Centre, Regina Margherita Children’s Hospital, Turin; 3Department of Child Pathology and Care “Regina Margherita”, SSD Pediatric Neurology, Regina Margherita Children’s Hospital, Turin, Italy
375 -
Manual trigger point treatment in migraine management: a scope review
1096PDF: 308SUPPLEMENTARY: 145 -
OC-16 | Network-level brain connectivity alterations in an animal model of migraine and the effects of olcegepant treatment Rosaria Greco,1 Gloria Castellazzi,1 Miriam Francavilla,1,2 Chiara Demartini,1 Sara Facchetti,1,2 Daniele Martinelli,1 Cristina Tassorelli1,2 | 1Headache Science and Neurorehabilitation Unit, IRCCS Mondino Foundation, Pavia; 2Department of Brain and Behavioral Sciences, University of Pavia, Italy
122 -
PO-09 | When migraine turns severe: a case of aura that lasts too long Alessandra Fera,1 Erica Agosto,1 Giulia Grasso,2 Cristina Vassia,2 Francesca Feyles,2 Carlotta Canavese,3 Sara Racalbuto,2 Antonia Versace2 | 1Department of Public Health and Pediatrics, University of Turin; 2Department of Pediatric Emergency, Pediatric Headache Centre, Regina Margherita Children’s Hospital, Turin; 3Department of Child Pathology and Care “Regina Margherita”, SSD Pediatric Neurology, Regina Margherita Children’s Hospital, Turin, Italy
385 -
PO-17 | A clinical guide to assess and manage altered pain sensitivity and cervical musculoskeletal impairments migraine patients. Part 1: Assessment and profiling Stefano Di Antonio,1,2 Lars Arendt-Nielsen,1 Matteo Castaldo1,3 | 1Department of Health Science and Technology, Center for Pain and Neuroplasticity (CNAP), SMI, School of Medicine, Aalborg University, Aalborg, Denmark; 2Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics and Maternal Child Health, University of Genoa; 3Department of Medicine and Surgery, Clinical Psychology, University of Parma, Italy
264 -
PO-90 | CAPSULASE® (PEA (palmitoylethanolamide), PHYTOSOME (quercetin from Sophora japonica L. 40% soy lecithin, microcrystalline cellulose, aerosil), CASPEROME (Boswellia serrata R., gum resin 40%, soy lecithin, microcrystalline cellulose, aerosil), bromelain 2 Ennio Pucci,1 Ludovica Pucci,2 Alberto Vercesio3 | 1Department of Nervous System and Behavioral Sciences, University of Pavia; 2Nutritional biologist, Master in Nutritional and Clinical Dietetics, University of Pavia, Italy; 3Scientific Advisor
442 -
OC-14 | Efficacy of eptinezumab during a migraine attack: preliminary data from an Italian multicenter real-world experience (the BEFREE study) Luisa Fofi,1 Claudia Altamura,1 Marilena Marcosano,1 Alberto Doretti,2 Francesca Pistoia,3 Antonio Granato,4 Simona Guerzoni,5 Michele Trimboli,6 Licia Grazzi,7 Danilo Antonio Montisano,7 Gianluca Avino,8 Gabriele Sebastianelli,9 Carla Fasano,10 Elisa Maria Piella,11 Nicoletta Brunelli,1 Luigi Francesco Iannone,5,12 Fabrizio Vernieri1 on behalf of the Italian Headache Registry (RICe) Study Group | 1Neurosonology and Headache Unit, Fondazione Policlinico Campus Bio-Medico, Rome; 2IRCCS Istituto Auxologico Italiano - Department of Neurology and Laboratory of Neuroscience - Milan; 3University of L’Aquila; 4Headache Center, Neurology Clinic, University of Trieste, University Hospital of Trieste; 5AOU Policlinico di Modena; 6Azienda Ospedaliera-universitaria "Renato Dulbecco", Catanzaro; 7Headache Center, Neuroalgology Dpt, IRCCS Foundation "Carlo Besta" Neurological Institute, Milan; 8SOC Neurologia, Ospedale Santo Stefano, USL Toscana Centro, Prato; 9La Sapienza University of Rome Polo Pontino, Latina; 10Headache and Cerebrovascular Diseases Center, Neurology Unit 2, Careggi University Hospital, Florence; 11Department of Neuroscience “Rita Levi Montalcini”, University of Turin; 12Università di Modena e Reggio Emilia, Italy
327 -
PO-88 | Can tamoxifen and metformin nullify efficacy of CGRP-mAbs migraine prophylaxis? Patrizia Rossi,1,2 Valentina Cima,2 Alessandro Burlina2 | 1Headache Center, 2Neurology Department, San Bassiano Hospital, Bassano del Grappa (VI), Italy
525 -
PO-42 | OnaBotulinumtoxin-A in chronic migraine patients with short or long disease history and psychiatric comorbidities: preliminary data from an Italian multicentric study (the BACH Study) Fabrizio Vernieri,1,2 Marilena Marcosano,2 Licia Grazzi,3 Danilo Antonio Montisano,3 Raffaele Ornello,4 Simona Sacco,4 Chiara Rosignoli,4 Alberto Doretti,5 Maria Albanese,6 Giovanna Viticchi,7 Nicoletta Brunelli, Luigi d’Onofrio,2 Luisa Fofi,1 Claudia Altamura,1,2 Patrizio Pasqualetti8 | 1Fondazione Policlinico Campus Bio-Medico, Roma, Italy; 2Università Campus Bio-Medico di Roma, Italy; 3Istituto Neurologico Besta, Milano, Italy; 4Università degli Studi l’Aquila, Italy; 5Istituto Auxologico, Milano, Italy; 6Policlinico Tor Vergata, Roma, Italy; 7Università Politecnica Marche, Italy; 8Sapienza Università di Roma, Italy
228 -
PO-23 | Hemicrania continua-like headache in familial SDHD-related paragangliomas: a diagnostic challenge A. Di Chirico, L. Curto, G. Procopio, L. Troilo, G. Siciliano, F. Baldacci, S. Gori | Neurology Unit, Department of Clinical and Experimental Medicine, University of Pisa-AOUP, Pisa, Italy
232 -
PO-77 | Real-world evidence of Atogepant efficacy in patients unresponsive to anti-CGRP monoclonals Matteo Cortinovis, Marco Bolchini, Paola Zavarise, Giulia Campana, Giorgio Dalla Volta | Headache Center, Istituto Clinico Città di Brescia, Gruppo San Donato, Brescia, Italy
364 -
PO-57 | Early treatment with atogepant improves sleep quality without sleep-related adverse events: a prospective observational study Alberto Boccalini,1 Luigi Francesco Iannone,1,2* Flavia Lo Castro,1 Daria Brovia,1 Marina Romozzi,3,4 Fabrizio Vernieri,5,6 Claudia Altamura,5,6 Simona Guerzoni1 | 1Digital and Predictive Medicine, Pharmacology and Clinical Metabolic Toxicology-Headache Center and Drug Abuse-Laboratory of Clinical Pharmacology and Pharmacogenomics, AOU Policlinico di Modena, Modena, Italy; 2Department of Biomedical, Metabolic, and Neural Science, University of Modena and Reggio Emilia, Modena, Italy; 3Dipartimento Universitario di Neuroscienze, Università Cattolica del Sacro Cuore, Rome, Italy; 4Neurologia, Dipartimento di neuroscienze, Organi di Senso e Torace, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy; 5Headache Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; 6Università Campus Bio-Medico di Roma, Italy
209 -
PO-68 | Bipolar disorder spectrum and psychopathology in cluster headache compared to migraine: a cross-sectional study in a hospital headache clinic Isabella Getuli, Giada Giuliani, Chiara Zilli, Simone Preti, Gaia Chiecchi, Lorenzo Tarsitani, Marta Altieri | Dipartimento di Neuroscienze Umane, Sapienza Università di Roma, Italy
336 -
PO-01 | Pediatric nummular headaches: a case series and physiopathological and nosography considerations Carola Meo¹*, Sofia D’Agostino¹*, Antonella Morea²*, Martina Tarantini²*, Giuseppe Giglia³, Maria Rosita Ruta⁴, Edvige Correnti⁵, Daniela D’Agnano², Giuseppe Santangelo⁵, Vittorio Sciruicchio², Vincenzo Raieli⁵ (*These authors contributed equally) | 1Child Neuropsychiatry Unit Department, Pro.M.I.S.E. "G. D'Alessandro", University of Palermo, Palermo, Italy; 2Children Epilepsy and EEG Center, San Paolo Hospital, ASL Bari, Bari, Italy; 3Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), Section of Human Physiology, University of Palermo, Palermo; 4Child Neuropsychiatry Unit, ASP 6, Palermo; 5Child Neuropsychiatry Department, ISMEP, ARNAS Civico, Palermo, Italy
252 -
PO-30 | A chronic migraine phenotype unveiling acromegaly: diagnostic pitfalls and the impact of timely treatment Cinzia Rita Tamborino, Gianni Difonzo, Adriana Fallacara, Damiano Paolicelli, Maria Pia Prudenzano | Headache Center, “L. Amaducci” Neurological Clinic, Policlinico General Hospital, Bari, Italy
342 -
OC-08 | Daily eletriptan significantly improves treatment-resistant cluster headache: a case series Andrea Burgalassi,1 Antonio Munafò,2 Francesco De Cesaris,1 Giulia Vigani,2 Alberto Chiarugi1,2 | 1Headache Center and Clinical Pharmacology Unit, Careggi University Hospital, Florence; 2Section of Clinical Pharmacology and Oncology, Department of Health Sciences, University of Florence, Florence, Italy
358 -
PO-21 | Evaluating the impact of anti-CGRP monoclonal antibodies on retinal features in migraine patients: a retrospective optical coherence tomography study Chiara Serafini,1 Massimo Cesareo,2 Alessio Martucci,2 Marco Lombardo,2 Vittoria Carla D’Agostino,1 Alessandro Stefani,3 Carlo Nucci,2 Nicola Biagio Mercuri,1,3 Maria Albanese1,3 | 1Regional Referral Headache Center, Neurology Unit, Tor Vergata University Hospital, Rome, Italy 2Ophthalmology Unit, Department of Experimental Medicine, University of Rome “Tor Vergata”, Rome; 3Department of Systems Medicine, University of Rome “Tor Vergata”, Rome, Italy
265 -
PO-82 | Integrated approach with detoxification, CGRP monoclonal antibodies and psychoeducational support in two patients with complex medication overuse headache Claudia Lanni,1 Federica Papini,2 Chiara Prevost,3 Alessandro Canessa,3 Lucia Testa,3 Cristoforo Comi,2 Delfina Ferrandi3 | 1Department of Psychology “Santi Antonio e Biagio”, University Hospital, Alessandria, Italy; 2Neurology Unit, Department of Transitional Medicine, University of Piemonte Orientale, and University Hospital “Maggiore della Carità”, Novara, Italy; 3Neurology Unit, “Santi Antonio e Biagio” University Hospital, Alessandria, Italy
257 -
OC-17 | Profiling miR-30a expression in patients with episodic and chronic migraine Elisa Rubino,1,2 Elisa Maria Piella,1 Giulia Cicilese,1,3 Silvia Boschi,1 Alberto Mario Chiarandon,1 Elena Tamagno,1,3 Michela Guglielmotto,1,3 Innocenzo Rainero1,2 | 1Department of Neuroscience “Rita Levi Montalcini”, University of Turin, Turin, Italy; 2Headache Center, Department of Neuroscience and Mental Health, AOU Città della Salute e della Scienza di Torino; 3Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano (TO), Italy
145 -
PO-38 | Impact of atogepant on achieving best possible quality of life among patient global impression of change responders Cristina Tassorelli,1 Pranav Gandhi,2 Molly Duan,2 Karen Carr,2 Kandavadivu Umashankar,2 Jonathan Stokes,2 Grace Forde,3 Tanya Bilchik,4 Martina Martini*, Rashmi Halker Singh5 | 1University of Pavia, Pavia, Italy; 2AbbVie, North Chicago, IL, USA; 3North American Partners in Pain Management, North New Hyde Park, NY, USA; 4Department of Neurology, Yale School of Medicine, New Haven, CT, USA; 5Mayo Clinic, Phoenix, AZ, USA *Abbvie Srl, Rome, Italy.
244 -
PO-91 | Real-world evidence of CGRP dual blockade: clinical and biomarker insights from combined therapy in chronic migraine Laura Marino,1 Marta Lioi1, Rosario Iannacchero,2 Michele Trimboli2 | 1Department of Neurology, Magna Graecia University, Catanzaro; 2Institute of Neurology, AOU Renato Dulbecco, Catanzaro, Italy
439